AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17688460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with olanzapine
Number of subjects: 100
Study 17688460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with risperidone
Number of subjects: 100
Study 17688460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with haloperidol
Number of subjects: 100
Study 17688460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with quetiapine
Number of subjects: 100
Study 17688460 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with agents like olanzapine, risperidone, haloperidol, or quetiapine
Number of subjects: 100
Study 17688460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies
Number of subjects: 100
Study 17688460 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 100
Study 15481160 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical IFN-alpha treatment for two weeks
Number of subjects: 6
Study 15481160 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 6
Study 15481160 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 6
Study 11156811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 204
Study 11156811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 9489823 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin at 6, 12, 50, 100, and 200 microg/kg/day
Number of subjects: 30
Study 9489823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet (food fiber 55 g/day)
Number of subjects: 0
Study 7817528 — intervention group
Group type: COMPARATOR
Intervention: Routine diet (food fiber 25 g/day)
Number of subjects: 0
Study 2847348 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH-DHE (1,500 U anti-Xa of LMWH + 0.5 mg DHE)
Number of subjects: 8
Study 2847348 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (5,000 IU)
Number of subjects: 8
Study 2847348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 30168896 — intervention group
Group type: EXPERIMENTAL
Intervention: ASI 500 U
Number of subjects: 369
Study 30168896 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA 500 U
Number of subjects: 369
Study 30168896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 369
Study 29073629 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure reduction (target systolic BP <140 mm Hg)
Number of subjects: 404
Study 29073629 — intervention group
Group type: COMPARATOR
Intervention: Contemporaneous guideline-recommended BP lowering
Number of subjects: 404
Study 24909188 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycopyrrolate (2%)
Number of subjects: 39
Study 24909188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23794519 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 115
Study 23794519 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological cardioversion
Number of subjects: 115
Study 22146253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist-manipulated border-molding technique
Number of subjects: 36
Study 22146253 — intervention group
Group type: COMPARATOR
Intervention: Patient-manipulated border-molding technique
Number of subjects: 36
Study 20029516 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogenic product (TP)
Number of subjects: 18
Study 20029516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 16969659 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (100 mJ/pulse, 10 Hz)
Number of subjects: 20
Study 16969659 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement with plastic curettes and antiseptic therapy (chlorhexidine digluconate 0.2%)
Number of subjects: 20
Study 16304572 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (allo-BMT) after four blocks of intensive chemotherapy
Number of subjects: 758
Study 16304572 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant (A-BMT) after four blocks of intensive chemotherapy
Number of subjects: 758
Study 16304572 — intervention group
Group type: COMPARATOR
Intervention: Four blocks of treatment
Number of subjects: 758
Study 16304572 — intervention group
Group type: EXPERIMENTAL
Intervention: Five blocks of treatment
Number of subjects: 758
Study 16304572 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC AML 12
Number of subjects: 758
Study 16304572 — intervention group
Group type: COMPARATOR
Intervention: MRC AML 10
Number of subjects: 758
Study 16304572 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of triple intrathecal chemotherapy for CNS-directed treatment
Number of subjects: 758
Study 16304572 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvements in supportive care
Number of subjects: 758
Study 16304572 — intervention group
Group type: EXPERIMENTAL
Intervention: Current MRC AML 15 trial
Number of subjects: 758
Study 16304572 — intervention group
Group type: COMPARATOR
Intervention: Standard MRC anthracycline-based consolidation
Number of subjects: 758
Study 11915005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 0
Study 9445329 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit (n=364)
Number of subjects: 802
Study 9445329 — intervention group
Group type: COMPARATOR
Intervention: General medical ward (n=438)
Number of subjects: 802
Study 8719697 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium fluorescein (DSF)
Number of subjects: 26
Study 8719697 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyfluorescein (CF)
Number of subjects: 26
Study 8719697 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group: Normal subjects)
Number of subjects: 26
Study 2718918 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-containing oral contraceptives (OCs)
Number of subjects: 0
Study 2718918 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (1700 micrograms vitamin A per capsule)
Number of subjects: 0
Study 2718918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplement (68,000 micrograms)
Number of subjects: 0
Study 2718918 — intervention group
Group type: COMPARATOR
Intervention: Control group (intrauterine contraceptive device (IUCD) users)
Number of subjects: 0
Study 822857 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (3 X 50 mg/day) + Thyrotrophin releasing hormone (TRH) (2 X 40 mg/day)
Number of subjects: 30
Study 822857 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (3 X 50 mg/day) + Placebo
Number of subjects: 30
Study 31624297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU vitamin D3 fortnightly for 4 months)
Number of subjects: 44
Study 31624297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pearl fortnightly for 4 months)
Number of subjects: 44
Study 26703981 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (450 mg/d caffeine content)
Number of subjects: 49
Study 26703981 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (12 mg/d caffeine content)
Number of subjects: 49
Study 26703981 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous low coffee users
Number of subjects: 49
Study 26703981 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous frequent coffee users
Number of subjects: 49
Study 26416895 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (GCSF) - filgrastim for 7 days or pegfilgrastim
Number of subjects: 407
Study 26416895 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 407
Study 26416895 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (GCSF)
Number of subjects: 407
Study 23504814 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylpentane (PMP) oxygenator
Number of subjects: 20
Study 23504814 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene (PPL) oxygenator
Number of subjects: 20
Study 21523716 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (35 mg/m² on days 1 and 8) plus S-1 (35 mg/m² each twice daily on days 1-14)
Number of subjects: 80
Study 21523716 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin (35 mg/m² each on days 1 and 8)
Number of subjects: 80
Study 21523716 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus S-1
Number of subjects: 80
Study 21523716 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin
Number of subjects: 80
Study 21523716 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC expression
Number of subjects: 80
Study 19397185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oportunidades program (conditional cash-transfer program)
Number of subjects: 0
Study 19397185 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19397185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oportunidades program
Number of subjects: 0
Study 19397185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oportunidades program and Control group
Number of subjects: 0
Study 16713529 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence self‐report tool
Number of subjects: 245
Study 16713529 — intervention group
Group type: COMPARATOR
Intervention: Electronic monitoring
Number of subjects: 245
Study 15461603 — intervention group
Group type: EXPERIMENTAL
Intervention: drugs + SLIT
Number of subjects: 511
Study 15461603 — intervention group
Group type: COMPARATOR
Intervention: drugs only
Number of subjects: 511
Study 11146520 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab Group (37 patients)
Number of subjects: 84
Study 11146520 — intervention group
Group type: COMPARATOR
Intervention: Non-Abciximab Group (47 patients)
Number of subjects: 84
Study 9388805 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent information exposure
Number of subjects: 190
Study 9388805 — intervention group
Group type: COMPARATOR
Intervention: Misleading information exposure
Number of subjects: 190
Study 9388805 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit questioning
Number of subjects: 190
Study 9388805 — intervention group
Group type: COMPARATOR
Intervention: Nonexplicit questioning
Number of subjects: 190
Study 7929503 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.03 microgram per kilogram of body mass)
Number of subjects: 92
Study 7929503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 3209626 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablets of levodopa-benserazide
Number of subjects: 16
Study 3209626 — intervention group
Group type: COMPARATOR
Intervention: Standard capsule of levodopa-benserazide
Number of subjects: 16
Study 28902028 — intervention group
Group type: EXPERIMENTAL
Intervention: A-101 40%
Number of subjects: 0
Study 28902028 — intervention group
Group type: EXPERIMENTAL
Intervention: A-101 32.5%
Number of subjects: 0
Study 28902028 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution
Number of subjects: 0
Study 28618234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera 3% ointment, 1 g twice daily for 4 weeks
Number of subjects: 20
Study 28618234 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment, 1 g twice daily for 4 weeks
Number of subjects: 20
Study 25141922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (100 ng/ml)
Number of subjects: 19
Study 25141922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 19
Study 23269816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) emulsion, 0.2 g/kg, 3 infusions before and after surgery
Number of subjects: 28
Study 23269816 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 28
Study 21194588 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic cleanser solution (Polident 3 Minutes)
Number of subjects: 116
Study 21194588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanser solution (Corega Tabs)
Number of subjects: 116
Study 21194588 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (NaOCl) solution
Number of subjects: 116
Study 21194588 — intervention group
Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 116
Study 18300086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pencil push-ups
Number of subjects: 221
Study 18300086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computer vergence/accommodative therapy and pencil push-ups
Number of subjects: 221
Study 18300086 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy with home reinforcement
Number of subjects: 221
Study 18300086 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy
Number of subjects: 221
Study 16226901 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol foam
Number of subjects: 75
Study 16226901 — intervention group
Group type: COMPARATOR
Intervention: Liquid polidocanol
Number of subjects: 75
Study 12633635 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial septal pacing
Number of subjects: 17
Study 12633635 — intervention group
Group type: COMPARATOR
Intervention: Combined pacing algorithm (atrial pacing preference; atrial rate stabilization; and post mode-switch overdrive pacing) in AT500 pacemakers
Number of subjects: 17
Study 12633635 — intervention group
Group type: COMPARATOR
Intervention: Atrial pacing preference activated in Pulsar Max group
Number of subjects: 17
Study 10883554 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 50
Study 10883554 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Number of subjects: 50
Study 10883554 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 50
Study 9218088 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate
Number of subjects: 12
Study 9218088 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide dinitrate
Number of subjects: 12
Study 9218088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1382879 — intervention group
Group type: COMPARATOR
Intervention: 1 mg.kg‐1 meperidine (Group 1, n = 30)
Number of subjects: 60
Study 1382879 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 meperidine plus 0.5 mg.kg‐1 prilocaine (Group 2, n = 30)
Number of subjects: 60
Study 1382879 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 meperidine plus 0.5 mg.kg‐1 prilocaine (Group 2)
Number of subjects: 60
Study 2856710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 12
Study 2856710 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.25 mg once daily)
Number of subjects: 12
Study 2856710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily) + Clonidine (0.25 mg once daily)
Number of subjects: 12
Study 2856710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30888598 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR Tyrosine Kinase Inhibitors (TKIs)
Number of subjects: 22
Study 30888598 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 22
Study 30888598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with EGFR TKIs followed by Crizotinib
Number of subjects: 22
Study 30888598 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR/ALK co-altered patients
Number of subjects: 22
Study 30888598 — intervention group
Group type: COMPARATOR
Intervention: EGFR-mutant patients
Number of subjects: 22
Study 30888598 — intervention group
Group type: COMPARATOR
Intervention: ALK-rearranged patients
Number of subjects: 22
Study 29695348 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy
Number of subjects: 1184
Study 29695348 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation (50 Gy with a boost of 10 Gy)
Number of subjects: 1184
Study 27537762 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg oral clonidine followed by 0.2 mg/d transdermal clonidine patch
Number of subjects: 624
Study 27537762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 24882587 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural restriction for 10 days after the modified Epley maneuver
Number of subjects: 78
Study 24882587 — intervention group
Group type: COMPARATOR
Intervention: No positional restriction after the modified Epley maneuver
Number of subjects: 78
Study 23144441 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive catheter care station (HubScrub and DOCit)
Number of subjects: 572
Study 23144441 — intervention group
Group type: COMPARATOR
Intervention: Standard caps with sterile, conventional open lumen 3-way stopcock set
Number of subjects: 572
Study 20189328 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency applied to the anterior 1/3 of the inferior choncha
Number of subjects: 40
Study 20189328 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency applied to the whole of the inferior choncha
Number of subjects: 40
Study 17945318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried-bonito broth (DBB)
Number of subjects: 31
Study 17945318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16085581 — intervention group
Group type: EXPERIMENTAL
Intervention: GFADS and 2-compartment kinetic analysis
Number of subjects: 13
Study 16085581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-compartment approach
Number of subjects: 13
Study 16085581 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative dynamic (82)Rb PET
Number of subjects: 13
Study 12071024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (preoperative, postoperative, and pre- and postoperative)
Number of subjects: 0
Study 12071024 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (preoperative, postoperative, and pre- and postoperative)
Number of subjects: 0
Study 12071024 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy combinations
Number of subjects: 0
Study 12071024 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy vs. Radiotherapy
Number of subjects: 0
Study 12071024 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 11592543 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS)
Number of subjects: 40
Study 11592543 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS)
Number of subjects: 40
Study 11592543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 40
Study 9219702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (radiotherapy: 18.5 Gy in five fractions of 3.7 Gy each; cisplatin: 80 mg/m² body surface area administered 0 to 2 days before radiotherapy)
Number of subjects: 282
Study 9219702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 282
Study 9219702 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 282
Study 8388950 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 gm single dose)
Number of subjects: 73
Study 8388950 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (7-day course)
Number of subjects: 73
Study 2953239 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0
Study 2953239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 30287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 48
Study 30287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 48
Study 30287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 48
Study 28414043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate, 25 mg weekly
Number of subjects: 80
Study 28414043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil, 1 g twice daily
Number of subjects: 80
Study 26590962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal methylene blue injection (IMBI)
Number of subjects: 0
Study 26590962 — intervention group
Group type: COMPARATOR
Intervention: Intradiscal isotonic saline with lidocaine and contrast (Control)
Number of subjects: 0
Study 23159208 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA with 30 mL of contrast media (CM) following 5 mL of CM at timing bolus
Number of subjects: 126
Study 23159208 — intervention group
Group type: COMPARATOR
Intervention: CCTA with 50 mL of CM following 10 mL of CM at timing bolus
Number of subjects: 126
Study 23159208 — intervention group
Group type: EXPERIMENTAL
Intervention: CT number-controlling system using the simple equation for CCTA following 5 mL of CM at timing bolus
Number of subjects: 126
Study 21437603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg kg body mass(‐1))
Number of subjects: 8
Study 21437603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mL flavoured sugar‐free drink)
Number of subjects: 8
Study 18458357 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg
Number of subjects: 24
Study 18458357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 24
Study 18458357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 24
Study 18458357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 800 mg
Number of subjects: 24
Study 16772453 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 605
Study 16772453 — intervention group
Group type: COMPARATOR
Intervention: Prudent Western diet
Number of subjects: 605
Study 12480560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day)
Number of subjects: 103